Modeling Retinal Degeneration Using Patient-Specific Induced Pluripotent Stem Cells
Author Information
Author(s): Jin Zi-Bing, Okamoto Satoshi, Osakada Fumitaka, Homma Kohei, Assawachananont Juthaporn, Hirami Yasuhiko, Iwata Takeshi, Takahashi Masayo
Primary Institution: RIKEN Center for Developmental Biology, Kobe, Japan
Hypothesis
Can patient-specific induced pluripotent stem cells (iPS cells) be used to model retinal degeneration and evaluate drug responses?
Conclusion
Patient-derived rod cells recapitulated the disease phenotype and exhibited different responses to specific drugs.
Supporting Evidence
- Patient-derived rod cells exhibited suitable immunocytochemical features and electrophysiological properties.
- Rod photoreceptors differentiated from patient iPS cells underwent degeneration in vitro.
- Oxidative stress markers were present in patient-derived rod photoreceptors.
- α-Tocopherol treatment increased the number of Rhodopsin+ cells in RP9 mutant cells.
Takeaway
Scientists took skin cells from patients with a type of eye disease and turned them into stem cells to study how the disease works and test treatments.
Methodology
Fibroblast cells from RP patients were reprogrammed into iPS cells, which were then differentiated into rod photoreceptor cells for analysis.
Potential Biases
Potential bias in patient selection and genetic variability among patients.
Limitations
The differentiation process requires a long time, and in vitro evaluations may not perfectly mimic in vivo conditions.
Participant Demographics
Five RP patients with distinct mutations in RP1, RP9, PRPH2, or RHO genes.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website